GSK closes sale of thrombosis brands to Aspen
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has completed the £700m sale of two thrombosis brands to South Africa's largest listed pharma company, Aspen. The previously announced deal (scripintelligence.com, 30 September 2013) closed following regulatory approval of the transaction. The majority of commercial operations will formally transfer to Aspen on 1 January 2014 with the remainder, as well as the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.The brands in question are Arixtra (fondaparinux) and Fraxiparine (nadroparin), which booked combined sales of £177m in the first half of 2013.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.